Drug Trial Radar · NCT01989754
A Study of the Effects of Canagliflozin (JNJ-28431754) on Renal Endpoints in Adult Participants With Type 2 Diabetes Mellitus
Last checked: Nov 19, 2026Latest source record: Dec 11, 2018 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
5,813
Actual
Start
Jan 16, 2014
Primary completion
Feb 23, 2017
Study completion Feb 23, 2017
Sponsor
- Lead sponsor
- Janssen Research & Development, LLCJohnson & Johnson (Janssen) (JNJ)
- Sponsor type
- Industry
- Collaborators
- The George Institute for Global Health, Australia
- First posted
- Nov 21, 2013
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 30 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to assess the effect of canagliflozin compared to placebo on progression of albuminuria in participants with Type 2 Diabetes Mellitus receiving standard care but with inadequate glycemic control and at elevated risk of cardiovascular events.
Conditions
- Diabetes Mellitus, Type 2
- Albuminuria
Interventions
PlaceboDrug
One placebo capsule taken orally (by mouth) once daily for 156 weeks
Canagliflozin, 100 mgDrug
One 100 mg capsule taken orally (by mouth) once daily
Canagliflozin, 300 mgDrug
One 300 mg capsule taken orally (by mouth) once daily
Primary outcomes
What the sponsor says the trial is designed to measure.
- Progression of AlbuminuriaTime frame: Up to 3 years
Locations
341 sites in 25 countries. Site status is shown where the registry gives one.
Site not named
Little Rock, Arkansas
Site not named
Carmichael, California
Site not named
Concord, California
Site not named
Pismo Beach, California
Site not named
Roseville, California
Site not named
Thousand Oaks, California
Site not named
Denver, Colorado
Site not named
Hollywood, Florida
Site not named
Jacksonville, Florida
Site not named
Miami, Florida
Site not named
New Port Richey, Florida
Site not named
Opa-locka, Florida
Site not named
Orlando, Florida
Site not named
Palm Harbor, Florida
Site not named
Tampa, Florida
Site not named
Meridian, Idaho
Site not named
Chicago, Illinois
Site not named
Valparaiso, Indiana
Site not named
Topeka, Kansas
Site not named
Louisville, Kentucky
Site not named
Mandeville, Louisiana
Site not named
Metairie, Louisiana
Site not named
Elkridge, Maryland
Site not named
Flint, Michigan
Site not named
Picayune, Mississippi
Site not named
Kansas City, Missouri
Site not named
St Louis, Missouri
Site not named
Washington, Missouri
Site not named
Omaha, Nebraska
Site not named
Las Vegas, Nevada
Site not named
Cornelius, North Carolina
Site not named
Hickory, North Carolina
Site not named
Mooresville, North Carolina
Site not named
Canal Fulton, Ohio
Site not named
Franklin, Ohio
Site not named
Mason, Ohio
Site not named
Oklahoma City, Oklahoma
Site not named
Beaver, Pennsylvania
Site not named
Levittown, Pennsylvania
Site not named
Norristown, Pennsylvania
Showing 40 of 341 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.